February 28, 2017 / 12:12 PM / in 9 months

Valeant Pharma's revenue falls for third straight quarter

Feb 28 (Reuters) - Valeant Pharmaceuticals International Inc reported a 12.9 percent fall in quarterly revenue on Tuesday, its third straight quarter of a double-digit percentage decrease, as sales declined across its businesses and realized prices fell.

Net loss attributable to Valeant widened to $515 million, or $1.47 per share in the fourth quarter ended Dec. 31, from $385 million, or $1.12 per share, a year earlier.

Revenue slipped to $2.40 billion from $2.76 billion.

Laval, Quebec-based Valeant has been trying to rebuild its business and regain investor confidence after it came under investigations over its accounting and pricing practices.

Reporting by Ankur Banerjee in Bengaluru

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below